VALN - Valneva Pharma Year-over-year net earnings per share growth for the last 12 months

Official company branding of Valneva Pharma (VALN)

Valneva SE (VALN) benefits from inelastic demand for tourist vaccinations and the uniqueness of its Chikungunya vaccine. The quarterly EPS growth trend captures the market response, where -136.90 serves as the current metric level. However, success depends on the approval of new products, while business resilience relies on streamlined European logistics and strict supply quality control.

Valneva Corp (VALN) Year-over-year net earnings per share change for the last twelve months: for the period 07/04/2022 - 11/12/2026

VALN (Valneva Vaccines): analytical breakdowns and indicator data

- market value and analyst target forecast:
Price Chart Valneva|VALN - Fair Value Consensus
- market capitalization statistics:
Market Valuation Valneva Pharma|VALN - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share Valneva|VALN - Book Valuation of Business|Market Cap to Net Assets Ratio valneva.com|VALN - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Capital Valneva SE|VALN - Long-Term Debt to Capital|Short-Term Debt to Equity Valneva SE|VALN - Company Debts|Debt to Book Capitalization Ratio Valneva Pharma|VALN - Company Long-Term Indebtedness|Company Short-Term Debts Valneva|Quick Liquidity Indicator valneva.com
- earnings and market multiples details:
VALN - Company Net Income|Projected Future Earnings Valneva SE|VALN - P/E Multiple|Projected Price to Earnings Valneva Pharma|VALN - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Valneva Pharma|VALN - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Valneva|VALN - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months valneva.com|VALN - Earnings per share growth in current year|Earnings growth forecast for next year Valneva SE
Fundamental valuation:Valneva SE
Flagship merchandise of Valneva SE

For Valneva SE (VALN), quarterly earnings per share (EPS) growth on GURU.Markets reflects the dynamics of net income attributable to a single ordinary share. This metric measures the percentage change of this value relative to the same period last year. This calculation reveals the efficiency of capitalizing on the scientific achievements of the company's elite virologists. A positive trend confirms the successful commercialization of vaccines. It is critical for investors to correlate these fluctuations with market cycle phases.

Key competitors

Gilead Sciences (GILD) - Year-over-year earnings per share growth for the last twelve months|Cidara Corp - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months NVAX|Quarterly EPS earnings growth CureVac Pharma|Year-over-year earnings per share growth for the last twelve months Vir Biotechnology, Inc. (VIR)|Year-over-year net earnings per share change for the last twelve months siga.com|Emergent BioSolutions Inc. - Year-over-year net earnings per share growth for the last 12 months|Atea Pharma - Year-over-year earnings per share growth for the last twelve months|Invivyd Corp - Quarterly EPS earnings growth|ENTA - Quarterly EPS earnings growth|Inovio Pharmaceuticals (INO) - Year-over-year earnings per share growth for the last twelve months|HLVX (hillevax.com) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months Kalaris Therapeutics|Year-over-year earnings per share growth for the last 12 months DYAI (Dyadic)|Quarterly EPS earnings growth NNVC|TLPH - Earnings per share growth in annualized terms for the last twelve months|Cocrystal Pharma, Inc. - Year-over-year net earnings per share growth for the last 12 months|Traws Pharma Inc - Year-over-year earnings per share growth for the last twelve months|Virios Therapeutics - Quarterly EPS earnings growth|QLGN - Quarterly EPS earnings growth|ALVR (allovir.com) - Year-over-year net earnings per share growth for the last 12 months|VBI Vaccines - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Virios Therapeutics Inc.|Vaxart Corp (VXRT) - Year-over-year net earnings per share change for the last twelve months